ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia. (October 2011)
- Record Type:
- Journal Article
- Title:
- ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia. (October 2011)
- Main Title:
- ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia
- Authors:
- L''Huillier, Arnaud G
Ing Lorenzini, Kuntheavy
Crisinel, Pierre-Alex
Rebsamen, Michela C
Fluss, Joel
Korff, Christian M
Barbe, Remy P
Siegrist, Claire-Anne
Dayer, Pierre
Posfay-Barbe, Klara M
Desmeules, Jules A - Abstract:
- Aims: To examine the safety profile of oseltamivir in children and evaluate the impact of P-glycoprotein polymorphisms on the incidence of neuropsychiatric adverse events (NPAE) in oseltamivir-treated children.Subjects & methods: This prospective cohort study was conducted in our tertiary care pediatric hospital (University Hospitals of Geneva, Switzerland) during the H1N1 pandemia, between 1 October 2009 and 31 January 2010. All newborn to 18 year-old patients presenting at the emergency department with a flu-like illness were eligible for inclusion. Adverse events were systematically recorded by pediatricians and/or by parents at home using a diary card, with a 30-day follow-up period. The causality assessment of oseltamivir in NPAE was performed by two clinical pharmacologists. After informed consent, enrolled patients were also genotyped for ABCB1 3435C>T (rs1045642) and 2677G>T/A (rs2032582) polymorphisms.Results: Among the 42 H1N1-infected, oseltamivir-treated children who were genotyped for ABCB1 3435C>T and 2677G>T/A variants, 36% presented NPAE. When examining the association between the diplotype and the development of NPAE, we observed that the frequency of NPAE displayed a 'genotype-trend effect'' with the variant and the wild-type subgroups at the two far ends. A total of 11% of the 2677GG–3435CC individuals (wild-type homozygous) presented NPAE, compared with 39% of the individuals being heterozygous for at least one variant allele and 67% of the 2677TT–3435TTAims: To examine the safety profile of oseltamivir in children and evaluate the impact of P-glycoprotein polymorphisms on the incidence of neuropsychiatric adverse events (NPAE) in oseltamivir-treated children.Subjects & methods: This prospective cohort study was conducted in our tertiary care pediatric hospital (University Hospitals of Geneva, Switzerland) during the H1N1 pandemia, between 1 October 2009 and 31 January 2010. All newborn to 18 year-old patients presenting at the emergency department with a flu-like illness were eligible for inclusion. Adverse events were systematically recorded by pediatricians and/or by parents at home using a diary card, with a 30-day follow-up period. The causality assessment of oseltamivir in NPAE was performed by two clinical pharmacologists. After informed consent, enrolled patients were also genotyped for ABCB1 3435C>T (rs1045642) and 2677G>T/A (rs2032582) polymorphisms.Results: Among the 42 H1N1-infected, oseltamivir-treated children who were genotyped for ABCB1 3435C>T and 2677G>T/A variants, 36% presented NPAE. When examining the association between the diplotype and the development of NPAE, we observed that the frequency of NPAE displayed a 'genotype-trend effect'' with the variant and the wild-type subgroups at the two far ends. A total of 11% of the 2677GG–3435CC individuals (wild-type homozygous) presented NPAE, compared with 39% of the individuals being heterozygous for at least one variant allele and 67% of the 2677TT–3435TT individuals (homozygous variants) (p = 0.149, nonsignificant).Conclusion: These observations suggest a potential influence of ABCB1 polymorphisms in oseltamivir-related NPAE, maybe as a result of an enhanced permeability of the blood–brain barrier to oseltamivir. Original submitted 26 April 2011; revision submitted 30th June 2011 … (more)
- Is Part Of:
- Pharmacogenomics. Volume 12:Number 10(2011)
- Journal:
- Pharmacogenomics
- Issue:
- Volume 12:Number 10(2011)
- Issue Display:
- Volume 12, Issue 10 (2011)
- Year:
- 2011
- Volume:
- 12
- Issue:
- 10
- Issue Sort Value:
- 2011-0012-0010-0000
- Page Start:
- 1493
- Page End:
- 1501
- Publication Date:
- 2011-10
- Subjects:
- adverse events -- anti-infective -- pediatrics -- pharmacogenetics -- psychiatric
Pharmacogenomics -- Periodicals
615.1 - Journal URLs:
- http://www.futuremedicine.com/loi/pgs ↗
http://www.futuremedicine.com/ ↗ - DOI:
- 10.2217/pgs.11.91 ↗
- Languages:
- English
- ISSNs:
- 1462-2416
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6446.249500
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 16519.xml